Ecraid supports WHO Industry Dialogue on Global Antibiotic Development
In partnership with WHO, Ecraid is helping shape more efficient, relevant, and globally aligned approaches to developing new antibiotics.
On 31 August 2026, the World Health Organization (WHO) AMR Department will convene developers of antibacterial agents targeting bacterial priority pathogens for a focused Industry Dialogue on Evidence Generation in Global Antibiotic Development.
Ecraid is pleased to support the organisation of this important dialogue, which will bring together industry stakeholders, experienced facilitators, and speakers from the field, to discuss some of the key challenges facing antibiotic development today. These include:
• Fragmented regulatory requirements
• Trade-offs in clinical trial design
• Gaps between the evidence generated for regulatory approval and the evidence needed to inform clinical use and antimicrobial stewardship
The key question is, How can evidence generation for priority antibiotics better support both regulatory approval and clinical use?
With more than 150 participants registered, the dialogue will provide an important opportunity to hear directly from developers and learn from real-world experiences of bringing new antibacterial agents through development. By bringing together perspectives from industry and the wider clinical research community, the dialogue aims to identify key challenges in evidence generation and help inform future WHO guidance on antibiotic development.
Have you registered?
📅 Monday, 31 August 2026
🕑 14:00 – 16:00 CET
📍 Online Meeting via Zoom